Hinova Pharmaceuticals Inc.

SHSE:688302 Stock Report

Market Cap: CN¥3.5b

Hinova Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Hinova Pharmaceuticals has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 50.8% per year.

Key information

2.3%

Earnings growth rate

29.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-50.8%
Return on equity-17.1%
Net Margin-191,539.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Companies Like Hinova Pharmaceuticals (SHSE:688302) Are In A Position To Invest In Growth

Oct 01
Companies Like Hinova Pharmaceuticals (SHSE:688302) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Hinova Pharmaceuticals' (SHSE:688302) Cash Burn Situation

May 13
Here's Why We're Not Too Worried About Hinova Pharmaceuticals' (SHSE:688302) Cash Burn Situation

Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Mar 14
Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Revenue & Expenses Breakdown

How Hinova Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688302 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-21063175
30 Jun 240-22974188
31 Mar 240-26682227
31 Dec 230-29488248
30 Sep 232-31791271
30 Jun 232-31993278
31 Mar 232-29093245
31 Dec 222-30297251
30 Sep 220-31998264
30 Jun 220-30690259
31 Mar 220-34388290
31 Dec 210-30680265
31 Dec 200-49062429
31 Dec 194-11213116
31 Dec 184-39749

Quality Earnings: 688302 is currently unprofitable.

Growing Profit Margin: 688302 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688302 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare 688302's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688302 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 688302 has a negative Return on Equity (-17.07%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies